A Phase 2 interventional study of RBD4059 and Placebo in Stable Coronary Artery Disease CAD, sponsored by Ribocure Pharmaceuticals AB. Completed at 1 site in Sweden. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-27.
Sponsored by Ribocure Pharmaceuticals AB (part of Suzhou Ribo Life Science Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 92 studies in Coronary Artery Disease with a site in Sweden — 14 open to participants now, 24 under way, 3 of them phase 3. Coronary Artery Disease · Sweden.
Among the 92 studies in Coronary Artery Disease with a site in Sweden, this one is the 66th largest by enrollment of the 71 interventional ones that give a count, is one of 4 that started in 2024, is one of 10 in phase 2, and was the 88th registered.
4,862 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.
Browse Coronary Artery Disease studies →14 of the 92 studies in Coronary Artery Disease with a site in Sweden are open now. Recruiting first, the newest first:
Vastra Gotaland Region · Sites in Sweden
Ages 18+
Uppsala University · Sites in Sweden
Ages 50–80
Region Skane · Sites in Sweden
Ages 40+ · Healthy volunteers
CSL Behring · Sites in Sweden, United States, Argentina and 32 more countries
Ages 18+
Region Östergötland · Sites in Sweden
Ages 18+
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.
This study: 50 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
92 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 12 · Phase 3 13 · Phase 4 5
First in 1992; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 124 across 3,009 interventional studies indexed under Coronary Artery Disease.
Median enrollment 500 across the 71 interventional studies, 1,356 across the 21 observational. Of the 62 that completed or were terminated, 22 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 92 have an industry lead sponsor. The 10 most frequent:
This study is registered under Ribocure Pharmaceuticals AB, one of the names counted as Suzhou Ribo Life Science Co., Ltd.. Under that name alone:
Ribocure Pharmaceuticals AB is the lead sponsor of 6 studies on the registry; 4 are open to participants now.
Suzhou Ribo Life Science Co., Ltd. has 2 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
2 of the studies in Coronary Artery Disease with a site in Sweden that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06578234Region SkaneHyperemic mYocardial Perfusion by adEnosine at diffeRent Doses | 2026-12-31 |
| NCT07884136Ribocure Pharmaceuticals ABRBD1119 in Coronary Artery Disease (CAD) | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 92 studies in Coronary Artery Disease with a site in Sweden, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn about the safety of drug RBD4059, and also if drug RBD4059 works to treat stable coronary artery disease in adults.
The main questions the trial aim to answer are:
What medical problems may participants experience when taking drug RBD4059? Researchers will compare drug RBD4059 to a placebo to see if drug RBD4059 works to treat stable coronary artery disease.
Participants will:
Receive drug RBD4059 or a placebo. Visit the clinic 11 or 12 times during 11 or 14 months for checkups and tests, depending on which treatment group they belong to.
Low-dose group The trial will start with the low-dose group. The screening period takes place between D-28 to D-1 including informed consent, and those who meet the inclusion criteria and not meet any exclusion criteria will return to the trial site for further evaluating at D1 to confirm enrolment in the trial.
Participants will be assigned and randomized to receive RBD4059 (n=10) or placebo (n=5). All participants will be dosed at the trial site and undergo blood sampling and examinations at pre-defined timepoints.
A SRC meeting will be conducted on data from day 36 (W5), including at least 9 participants in the low-dose group. Provided acceptable safety profile of the low dose group, data from this SRC meeting will be used to guide initiation of the high-dose group.
Participants will return to the site and be monitored for safety and efficacy throughout the trial. Safety will be monitored until D336 (Week 48).
High-dose group This group will be initiated when the 36-day SRC meeting of the low-dose dose cohort has been conducted with no significant safety issues established. For the high-dose group, the screening period takes place between D-28 to D-1 including informed consent, and those who meet the inclusion criteria and not meet any exclusion criteria will return to the trial site for further evaluating at D1 to confirm enrolment in the trial.
Participants will be assigned and randomized to receive RBD4059 (n=10) or placebo (n=5). All participants will be dosed at the trial site and undergo blood sampling at pre-defined timepoints.
Participants will return to the site and be monitored for safety and efficacy throughout the trial until D426 (Week 60).
In both treatment groups, a switch from treatment with aspirin 75 mg to the equivalent AMP (Trombyl 75 mg) will be initiated on D1 and continue to the end of the study.
Inclusion Criteria:
Main exclusion Criteria:
History or presence of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive RBD4059 as subcutaneous injections
Drug: RBD4059
Participants will receive placebo as subcutaneous injections
Drug: Placebo
Participants will receive RBD4059 as subcutaneous injections
Drug: RBD4059
Participants will receive placebo as subcutaneous injections
Drug: Placebo
RBD4059, active drug.
Placebo that is identical in appearance and volume to the doses of active IMP.
Frequency, intensity and seriousness of reported AEs, SAEs and AEs of special interest (AESIs) during the trial.
Number and percentage of participants with AEs, SAEs and AEs of interest. All reported AE terms will be coded using Medical Dictionary for Drug Regulatory Affairs (MedDRA).
Time frame: From baseline until end of trial at week 48 or 60, depending on the dose group.
Plasma concentrations of RBD4059.
Time frame: In conjunction of administration of the IMP
Change and percent change compared with pre-dose baseline of FXI activity at different time points in each group.
Time frame: From baseline until end of trial at week 48 or 60, depending on the dose group.
Proportion of participants with positive immunogenicity, measured as plasma concentrations of anti-drug antibodies (ADAs)
Time frame: From randomization until end of trial at week 48 or 60, depending on the dose group.
Change and percent change compared with pre-dose baseline of APTT and PK(INR) at different time points in each group.
Time frame: From baseline until end of trial at week 48 or 60, depending on the dose group.
Change and percent change compared with pre-dose baseline of platelet inhibition at different time points in each group.
Time frame: From randomization until week 48
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Aug 2024 to primary completion in Apr 2026, 20 months.
Of 26 industry-sponsored phase 2 interventional studies under Coronary Artery Disease, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 29. This study's 20 months is above that.
Counting every sponsor, half of 55 studies reached it within 28 months; a quarter within 16 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: RBD4059